NCT05046522View on ClinicalTrials.gov

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Migraine
Interventions
DRUG

Palmitoylethanolamide sold as Levagen +

Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.

DRUG

Placebo comparator - maltodextrin and microcrystalline cellulose mix

Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.

Trial Locations (1)

4006

RDC Global Pty Ltd, Brisbane

All Listed Sponsors
lead

RDC Clinical Pty Ltd

INDUSTRY

NCT05046522 - A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines. | Biotech Hunter | Biotech Hunter